Peptides
Adipotide
Also called FTP peptide
Adipotide attracts people looking for direct fat reduction rather than appetite suppression. It targets the blood supply supporting fat tissue, but the same research that made it interesting also found kidney injury signals; a dependable human benefit-to-risk balance is not established.
Dosage & duration
Human dosing questions remain unresolved after reviewing original research and reported use.
Human fat-loss use
Published example · product-specific- Dose
- No established effective and safe human dose
- How often
- No validated human schedule
- How long
- No established human cycle
The original primate treatment lasted four weeks; that is animal-study context, not a human course.
Sources: 1
Dose-dependent kidney findings make a copied or animal-scaled protocol particularly unreliable.
The original research
Fat-loss findings came with a kidney concern
What drew interest
-
Fat reduction
Obese monkeys lost weight in the cited adipotide experiment.
What raises concern
-
Kidney changes
The same study found dose-dependent kidney injury signals.
Why the fat-loss claim stands out
The proposed approach is to disrupt vessels that support white fat tissue. Weight loss in obese monkeys sparked interest, but it does not show that a purchased vial can selectively remove a person’s belly fat.
The kidney issue is part of the original evidence
The primate study found dose-dependent kidney changes. Feeling fine, staying hydrated or adding a “kidney support” peptide does not demonstrate protection against those effects. Reports of reversibility in animals are not a promise of recovery in people.
What user reports can and cannot tell you
People report both enthusiasm and disappointing results, alongside concerns about cost and injection reactions. These experiences do not establish a reliable effective dose or a safe threshold. Do not scale a monkey dose into a personal fat-loss plan.
Model details: Adipotide · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.96 hours
- Absorption half-life assumed
- 0.24 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- No matched human concentration/time endpoint was verified. Do not translate the primate experimental regimen into human calibration.
- Barnhart et al. 2011: peptidomimetic targeting white fat
Original work concerns obese Old World monkeys; it is not a calibration study in human users.
adipotide-relative-timing-2026-10 · version 1
Common questions
Does adipotide remove belly fat specifically?
The monkey research does not establish targeted human belly-fat removal.
Can extra hydration or another peptide prevent kidney harm?
No protective regimen is established by the cited evidence.
Sources Labels, studies and notes behind this guide
Catalog evidence: Other human research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Sought-after result
- An experimental goal, not established spot-fat removal.
- Critical trade-off
- These were observed in the original animal research.
- Human cycle
- Personal reports cannot resolve the dose-risk balance.
- 1. Barnhart et al. — adipotide in obese monkeys
Original primate experiment found weight loss and dose-dependent kidney changes. Animal recovery does not establish human safety.
- 2. Barnhart et al. 2011: peptidomimetic targeting white fat
Original work concerns obese Old World monkeys; it is not a calibration study in human users.
- 3. Barnhart et al. 2011 — adipotide in obese monkeys
Animal fat-loss and insulin-resistance findings, with renal proximal-tubule changes.
- 4. Kolonin et al. 2004 — adipose vascular targeting
Mouse experiments identify prohibitin-targeting motif and vascular-ablation mechanism.
- 5. ClinicalTrials.gov — NCT01262664
Registry/API checked: terminated phase 1, actual enrollment four; advanced prostate cancer and obesity, not an obesity efficacy trial.
Related compounds and examples
Related compounds
Semaglutide Injection (Ozempic/Wegovy)
Semaglutide can reduce hunger and food intake, helping people lose weight. Wegovy injections are prescribed for weight management; Ozempic injections treat type 2 diabetes. Both are taken weekly, with gradual dose increases to help manage digestive side effects.
Semaglutide Oral (Rybelsus)
Oral semaglutide offers a daily tablet option for adults with type 2 diabetes who want to avoid injections. The morning routine matters: food, drink and other tablets affect absorption, and different semaglutide products cannot be compared milligram for milligram.
Tirzepatide (Mounjaro)
Tirzepatide can reduce appetite and food intake, helping people lose weight and improve blood-sugar control. In the US, Zepbound is the weight-management brand and Mounjaro treats type 2 diabetes. Both are weekly injections; digestive side effects and the right dose for the treatment goal are the main practical trade-offs.